TickerGuard
Buy Day today: Neutral (46) Mixed market breadth · no major macro event
CHRS

Coherus BioSciences Inc

Healthcare · Biotechnology

0.8301$ -7.6% vs. previous close Closing price · As of: Oct 30, 2026

Ownership

Ownership Structure

Who owns Coherus BioSciences Inc (CHRS)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 87.8% of the shares are freely tradable; institutional investors hold 38.6%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 38.6%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 18.7%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 87.8%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 15.6%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 155Mio.

Largest Shareholders

Institutions

Institutions CHRS
Name Stake (%) Shares Change (%) Date
Timothy G. Youngquist 2020 Irrevocable Trust 8.45 13,050,623 +6.2 06/30/2026
BlackRock Inc 7.77 12,003,316 +15.8 06/30/2026
Vanguard Capital Management, LLC 3.85 5,949,490 +9.1 06/30/2026
Geode Capital Management, LLC 2.39 3,685,567 +18.1 06/30/2026
Samsara BioCapital, LLC 2.22 3,428,571 +0.0 06/30/2026
Kohlberg Kravis Roberts & Co LP 1.97 3,036,076 +0.0 06/30/2026
State Street Corp 1.54 2,382,305 +2.4 06/30/2026

Funds

Funds CHRS
Name Stake (%) Shares Change (%) Date
iShares Russell 2000 ETF 4.23 6,542,444 +100.0 09/30/2026
Vanguard MStar Total Stk Mkt Idx Invest 2.56 3,953,617 +0.0 09/30/2026
HBM Healthcare Investments AG Ord 2.40 3,714,285 +0.0 06/30/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Data as of: October 30, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?